Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04098770
Recruitment Status : Recruiting
First Posted : September 23, 2019
Last Update Posted : February 8, 2021
Sponsor:
Collaborators:
The 6th people's Hospital of Xinjiang province
The 4th people's hospital of Nanning City
The 3th people's hospital of Shenzhen City
Shanghai Public Health Clinical Center
Information provided by (Responsible Party):
Fu-Sheng Wang, Beijing 302 Hospital

Brief Summary:
Combined antiretroviral therapy (ART) efficiently suppresses viral replication and markedly decreases mortality among patients with HIV-1 infection/AIDS. While the advanced AIDS patients with CD4+T cell count less than 200 cells/µL often develop seriously opportunistic infections (OIs), severe wasting syndrome, and other fatal complications, which are the major causes of death in these patients. There has been no effective immune therapy for advanced AIDS patients who had a high mortality rate even in the era of cART. This clinical trail is to inspect the efficiency of allogeneic adoptive immune therapy for advanced AIDS patients.

Condition or disease Intervention/treatment Phase
AIDS Patients Biological: Allogeneic Adoptive Immune Therapy Phase 2

Detailed Description:

Combined antiretroviral therapy (ART) efficiently suppress viral replication and dramatically decrease mortality of the disease in HIV-1/AIDS patients.1 While in cART naive patients with chronic human immunodeficiency virus-1 (HIV-1) infection often characterized by HIV-1 replication, immune activation and deficiency, which lead to profound and systematic inflammation and pathoglogical change, especially in the AIDS patients with CD4 T count less than 50/uL, who often develop deadly complications, which accounts for the major cause of death group in spite of cART era. Up-to-date, there are no effective immune interventions to restore host holistic immunity for advanced AIDS patients.

In pre-cARTera, HLA-matched lymphocytes or stem cell transplantation had been exploratively used in AIDS patients. However, this kind of therapy failed for immunological reconstitution due to the lack of antiviral therapy to suppress HIV-1 replication at that time. With the advent of cART, allogeneic HLA-matched or mismatched lymphocytes or stem cell transplantations were mainly used for AIDS patients with hematopoietic malignancies, the Berlin and London patients were the cured pateints. However, allogeneic transplantation can not be used outside the setting of hematopoietic malignancies. In addition, the high frequency of GVHD (Graft-versus-host disease) owning to a transient or long-lasting engraftment is inevitable.

Until now, there has been no report of effective immune therapy for late-stage AIDS patients with acquired immunodeficiency and severe opportunistic infections (OIs). The urgent challenge is how to efficiently restore the host holistic immunity in AIDS patients at late stage.

The investigators have recently developed a mismatched allogeneic adoptive immune therapy (AAIT) protocol in combination with cART, and found that the treatment was safety and tolerability in a phase I study. The purpose of this study is to further investigate the efficacy of allogeneic adoptive immune therapy (AAIT) for advanced AIDS patients. 120 patients received i.v. transfusion one round (2-3 times) of 2.0-3.0*10E8 cells/kg of MNSs as the treated group, all of these patients received the conventional cART treatment. In addition, the equal 120 patients received cART were used as control. The side effects, CD4 T cell numbers, HIV viral load, clinical symptoms improvement, control of opportunistic infections, AIDS-related events and non-AIDS related events will be evaluated during the 96-week follow up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficiency of Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients
Actual Study Start Date : October 11, 2019
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2023

Arm Intervention/treatment
Experimental: Conventional treatment plus Allogeneic Adoptive Immune Therapy
Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
Biological: Allogeneic Adoptive Immune Therapy
A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients

No Intervention: Conventional treatment
Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received



Primary Outcome Measures :
  1. The change of CD4+ T cell count between AAIT treatment group and conventional group [ Time Frame: At Baseline , week 4,12, 24, 48 and 96 ]
    Marker for host immunity

  2. The change of survival between AAIT treatment group and conventional group [ Time Frame: At week 24, 48 and 96 ]
    Marker for efficacy of treatment


Other Outcome Measures:
  1. Side effects in the AAIT treatment group [ Time Frame: At Baseline, week 1, 2 , 4 and 24 ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  2. The occurence of clinical events including AIDS-related events and non-AIDS related events in the two groups [ Time Frame: At baseline, week 24, 48, 84 and 96 ]
    Marker for efficacy of treatment

  3. The change of plasma RNA copies/mL between AAIT treatment group and conventional group [ Time Frame: At Baseline, week 1, 4, 12, 24, 48, 84 and 96 ]
    Marker for HIV viral load

  4. The change of plasma HIV DNA between AAIT treatment group and conventional group [ Time Frame: At Baseline and week 1, 12, 24 and 48 ]
    Changes of HIV DNA in PBMC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, aged at 18 years (including) -65 years old
  2. Advanced AIDS patients with AIDS-related events
  3. Advanced patients with CD4 count less than or equal to 200 cells/uL, including end-stage patients with CD4 count less than or equal to 50 cells/uL before entry and at screening
  4. Sign informed consent, do not participate in other clinical trails during the period

Exclusion Criteria:

  1. Pregnancy, lactation and those who are not pregnant but do not take effective contraceptives measures
  2. Combined with other serious organic diseases while didn't related with AIDS
  3. HIV-2 infection
  4. Allergic to blood products
  5. Under long term immunosuppressive therapy
  6. Combined with malignant tumors
  7. Drug addicts within half-one year before the test
  8. Poor compliance to antiviral therapy; take part in other clinical trials at present

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04098770


Contacts
Layout table for location contacts
Contact: Ruonan Xu, MD 86-10-66933333 xuruonan2004@aliyun.com

Locations
Layout table for location information
China, Beijing
Beijing 302 Hospital of China Recruiting
Beijing, Beijing, China, 100039
Contact: Fu-Sheng Wang, MD    01066933328    fswang302@163.com   
Principal Investigator: Fu-Sheng Wang, MD         
Sponsors and Collaborators
Beijing 302 Hospital
The 6th people's Hospital of Xinjiang province
The 4th people's hospital of Nanning City
The 3th people's hospital of Shenzhen City
Shanghai Public Health Clinical Center
Investigators
Layout table for investigator information
Study Director: Fu-Sheng Wang, MD Beijing 302 Hospital
Publications:
Layout table for additonal information
Responsible Party: Fu-Sheng Wang, Head of Treatment and Research Center for Infectious Diseases, Principle Investigator, Clinical Professor, Beijing 302 Hospital
ClinicalTrials.gov Identifier: NCT04098770    
Other Study ID Numbers: 302-2019-05
First Posted: September 23, 2019    Key Record Dates
Last Update Posted: February 8, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fu-Sheng Wang, Beijing 302 Hospital:
AIDS patients
Safety
Efficiency
Immune Therapy